Table 3.
P values for pairwise comparison of on-study annualized relapse rate
| White (ARR 0.24) | AQP4 + White (ARR 0.21) | Black (ARR 0.24) | AQP4 + Black (ARR 0.22) | Asian (ARR 0.11) | AQP4 + Asian (ARR 0.07) | Latino (ARR 0.30) | AQP4 + Latino (ARR 0.34) | |
|---|---|---|---|---|---|---|---|---|
| Race only | ||||||||
| White (ARR 0.24) | Ref. | 0.912 | 0.024 | 0.392 | ||||
| AQP4 + White (ARR 0.21) | Ref. | 0.707 | 0.008 | 0.046 | ||||
| Black (ARR 0.24) | Ref. | 0.041 | 0.405 | |||||
| AQP4 + Black (ARR 0.22) | Ref. | 0.007 | 0.131 | |||||
| Asian (ARR 0.11) | Ref. | 0.013 | ||||||
| AQP4 + Asian (ARR 0.07) | Ref. | 0.001 | ||||||
| Latino (ARR 0.30) | Ref. | |||||||
| AQP4 + Latino (ARR 0.34) | Ref. | |||||||
| Female only | White (ARR 0.26) | AQP4 + White (ARR 0.21) | Black (ARR 0.19) | AQP4 + Black (ARR 0.20) | Asian (ARR 0.07) | AQP4 + Asian (ARR 0.08) | Latino (ARR 0.31) | AQP4 + Latino (ARR 0.35) |
|---|---|---|---|---|---|---|---|---|
| White (ARR 0.26) | Ref. | 0.197 | 0.003 | 0.483 | ||||
| AQP4 + White (ARR 0.21) | Ref. | 0.778 | 0.020 | 0.040 | ||||
| Black (ARR 0.19) | Ref. | 0.030 | 0.123 | |||||
| AQP4 + Black (ARR 0.20) | Ref. | 0.036 | 0.042 | |||||
| Asian (ARR 0.07) | Ref. | 0.003 | ||||||
| AQP4 + Asian (ARR 0.08) | Ref. | 0.001 | ||||||
| Latino (ARR 0.31) | Ref. | |||||||
| AQP4 + Latino (ARR 0.35) | Ref. |
| Male only | White (ARR 0.15) | AQP4 + White (ARR 0.18) | Black (ARR 0.65) | AQP4 + Black (ARR 0.52) | Asian (ARR 0.29) | AQP4 + Asian (ARR 0.00) | Latino (ARR 0.22) | AQP4 + Latino (ARR 0.14) |
|---|---|---|---|---|---|---|---|---|
| White (ARR 0.15) | Ref. | 0.006 | 0.317 | 0.651 | ||||
| AQP4 + White (ARR 0.18) | Ref. | 0.062 | 1.000 | 0.813 | ||||
| Black (ARR 0.65) | Ref. | 0.272 | 0.241 | |||||
| AQP4 + Black (ARR 0.52) | Ref. | 1.000 | 0.276 | |||||
| Asian (ARR 0.29) | Ref. | 0.785 | ||||||
| AQP4 + Asian (ARR 0.00) | Ref. | 1.000 | ||||||
| Latino (ARR 0.22) | Ref. | |||||||
| AQP4 + Latino (ARR 0.14) | Ref. |
On-study relapses included those that began up to 90 days before study start
AQP4 + , anti–aquaporin 4 seropositive; ARR, annualized relapse rate
Bold, significant difference at the P < 0.05 level